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ABSTRACT: The protozoan parasite Trypanosoma brucei is the
causative agent of African sleeping sickness, and there is an urgent
unmet need for improved treatments. Parasite protein kinases are
attractive drug targets, provided that the host and parasite kinomes
are sufficiently divergent to allow specific inhibition to be achieved.
Current drug discovery efforts are hampered by the fact that
comprehensive assay panels for parasite targets have not yet been
developed. Here, we employ a kinase-focused chemoproteomics
strategy that enables the simultaneous profiling of kinase inhibitor
potencies against more than 50 endogenously expressed T. brucei
kinases in parasite cell extracts. The data reveal that T. brucei
kinases are sensitive to typical kinase inhibitors with nanomolar potency and demonstrate the potential for the development of
species-specific inhibitors.
The protozoan parasite Trypanosoma brucei is transmittedby the bite of an infected Tsetse fly and causes African
sleeping sickness, which is also known as Human African
Trypanosomasis (HAT). The disease is invariably fatal if left
untreated and results in upward of 10,000 deaths each year in
sub-Saharan Africa.1 T. brucei has a complex digenetic lifecycle
between the insect vector and mammalian host, and the ability
to adapt to these environments is essential to its survival and
virulence. During early stages of infection the clinically relevant
bloodstream form of the parasite proliferates in the blood and
lymph of the human host and then in the second stage enters
the cerebrospinal fluid and brain, resulting in coma and death.
Current treatments are expensive, toxic, and difficult to
administer, leaving an urgent unmet need for improved
therapeutic agents.2
Protein kinases play key roles in the control of growth and
cell signaling and are a major target of the pharmaceutical
industry. Parasite protein kinases have been proposed as
attractive targets for drug discovery as such efforts can “piggy-
back” on the extensive knowledge of the development of
inhibitors against human protein kinases.3 In the case of T.
brucei, bioinformatic analysis of the genome has identified 176−
182 putative protein kinases on the basis of sequence similarity,
the majority of which can be placed within well-recognized
kinase groups (Supplementary Table S1).4,5 Efforts to
determine the detailed biological role of T. brucei protein
kinases are ongoing, although knock-down by RNA interfer-
ence has provided evidence of the essential nature of a
significant number of protein kinases.6 However, the rationale
to develop drugs to target the T. brucei kinome poses a
conundrum: if mammalian and parasite protein kinases are
sufficiently similar to be identified and classified on the basis of
sequence similarity and are inhibited by typical inhibitors, will
parasite kinase inhibitors lack host−parasite specificity?
Conversely, if the kinases are sufficiently different that host−
parasite specificity can be readily obtained, will they be
inhibited by typical inhibitors of mammalian kinases? In
other words, we need to consider the similarity of the chemical
space that parasite and mammalian protein kinase inhibitors
occupy, rather than the similarity in protein kinase sequence.
One way to probe the inhibitor chemical space is to profile
inhibitor activity against both the mammalian and parasite
kinomes. Such profiling is often achieved using in vitro activity
assays against a panel of recombinant protein kinases,7 but
there is no such panel available for the T. brucei kinome; indeed
only a handful of active T. brucei kinases have been
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Figure 1. Chemical proteomics approach to profiling the targets of kinase inhibitors. T. brucei cell lysates are incubated in the presence or absence of
the test inhibitor prior to the addition of mixed kinase-inhibitor beads (kinobeads) to enrich kinases and related proteins. The presence of the test
kinase inhibitor prevents the binding of its target(s) to the kinobeads. Analysis of the kinobead-bound subproteome by quantitative tandem mass
spectrometry using isobaric tags allows inhibition curves to be calculated for each protein observed.
Figure 2. Profiling the kinome expressed in bloodstream form T. brucei using complementary mass spectrometry-based observations. (a) Venn
diagram summarizing overlapping protein kinase observations. (b) Details of protein kinases observed (black square), divided by kinase group
classification according to the similarity of their catalytic domains. Proteome: detection at natural abundance. Phosphorylated: enrichment of
phosphorylated peptides.5 Kinobeads: enriched by immobilized mixed kinase-inhibitors.
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recombinantly expressed as active enzymes.8−10 A recent
advance in kinase inhibitor profiling uses a chemical proteomic
methodology that captures a substantial portion of the
expressed kinome (and related proteins) contained in cell
lysates on a mixed kinase-inhibitor matrix known as
kinobeads.11,12 Addition of a kinase inhibitor to the cell lysates
enables it to bind to its specific target(s), occupying the binding
sites and preventing binding to the kinobeads, whereas the
binding of nontargeted kinases and other proteins are
unaffected. Incubation of the lysate with varying concentrations
of the inhibitor and subsequent analysis of the kinobead-bound
subproteome by quantitative mass spectrometry allows
inhibition curves to be generated for each protein observed
(Figure 1). We reasoned that this methodology should be
species independent, provided that the kinobeads are
sufficiently promiscuous to capture a sizable portion of the
parasite kinome.
Here, we present the results of our efforts to establish
kinobead chemoproteomics profiling in T. brucei and estimate
the coverage of the parasite kinome. Our strategy enabled us to
access more than 50 parasite kinases for inhibitor profiling,
which by far exceeds any currently available enzyme panels. We
report the profile of the mammalian kinase inhibitors
staurosporine and BMS-387032 and several early hit com-
pounds identified as parasite protein kinase inhibitors by the
Drug Discovery Unit at the University of Dundee.
■ RESULTS AND DISCUSSION
Coverage of the T. brucei Kinome. Kinobeads consist of
immobilized analogues of a variety of ATP competitive kinase
inhibitors that show relatively promiscuous binding to the
mammalian kinases, but their ability to bind kinases from more
divergent organisms has not been examined. To establish to
what extent T. brucei protein kinases were able to bind to the
kinobeads, we examined the subproteome enriched from cell
Figure 3. Chemical proteomics profiling of Staurosporine and BMS-387032 against the trypanosome and human kinome. Horizontal bars represent
IC50 value calculated from the isobaric reporter signals, gray bars indicate where binding was not quantified. Lysates were incubated with varying
concentrations of compounds prior to incubation with kinobeads, and the bound fraction was quantified by tandem mass spectrometry. Data for TK,
TKL, atypical, and lipid kinase are not shown for clarity; the full data for the trypanosome profile can be found in Supplementary Table S5, and the
CLL cell data has been reported previously.17
ACS Chemical Biology Articles
dx.doi.org/10.1021/cb300326z | ACS Chem. Biol. 2012, 7, 1858−18651860
lysates of the clinically relevant bloodstream form of T. brucei.
Initially, we compared four versions of kinobeads that differ in
the identity of the immobilized inhibitors (see Methods). In
these experiments, we observed the enrichment of a total of a
57 protein kinases (Supplementary Table S2). The enrichment
of a significant number of trypanosome protein kinases by these
promiscuous mammalian kinase inhibitors suggests that the
ATP binding pocket architecture is broadly conserved between
the two species.
Estimating the portion of the trypanosome kinome captured
is not straightforward, as the bloodstream form represents just
one of the multiple lifecycle stages of T. brucei and may not
express every kinase encoded by the genome. Before we could
determine the proportion of the bloodstream form kinome that
was captured by kinobeads, we needed to estimate how many
protein kinases were present in the cell lysates. To achieve this,
we took advantage of the differing bias of two orthogonal
proteomic techniques. By analyzing the total proteome
contained in the non-enriched cell lysate we identified the
most abundant 3248 proteins, which included 90 protein
kinases (Supplementary Table S3). This data shows good
overlap with a recent comparative SILAC proteomic study of
the bloodstream and procyclic form T. brucei, which identified
65 protein kinases,13 including 18 not seen in this study. A
separate phosphoproteomic study by Nett et al.,5 which used
strong cation exchange and TiO2 chromatography to enrich for
phosphopeptides, identified 43 phosphorylated protein kinases
in bloodstream form T. brucei. Comparison of the protein
kinases identified by these three orthogonal proteomics
techniques revealed overlapping and complementary coverage
of the bloodstream form kinome (Figure 2 and Supplementary
Table S4), providing experimental observation of a total of 124
protein kinases out of the predicted 182 (68%). The kinases
that bind to kinobeads are not significantly biased toward
abundant (Supplementary Figure S1) or phosphorylated
protein kinases or any particular kinase group. Mapping the
kinases that bind to kinobeads onto the phylogeny of the T.
brucei kinome shows that kinobead enrichment appears to be
independent of the degree of sequence homology (Figure 2).
While it is likely that the coverage of this observable
bloodstream form kinome is not complete, it is in reasonable
agreement with transcriptome studies that suggest 25% of the
genome is differentially expressed between bloodstream and
procyclic form T. brucei cells.14 The kinobead-enriched
subproteome contains 46% of the observed bloodstream form
kinome (31% of the predicted genome), comparable to the
coverage obtained from analysis of human cell lysates (52% of
the predicted genome).
Profiling of Known Kinase Inhibitors. Kinobead-based
profiling enables access to a sizable fraction of the expressed
trypanosome kinome, which can be used to determine the
potency and selectivity of kinase inhibitors in cell extracts by
means of a multiplexed competition binding assay. The
kinobeads version producing the best coverage of the T. brucei
kinome was used to determine the kinase inhibition profile of
two well-studied kinase inhibitors: Staurosporine and BMS-
387032. The binding of these inhibitors to their cellular targets
was quantified by mass spectrometry using isobaric tags for
relative and absolute quantification (iTRAQ)15,16 for 51 protein
kinases and 67 other kinobead-binding proteins (Figure 3 and
Supplementary Table S5). Staurosporine, a natural product, is a
prototypical ATP-competitive pan-kinase inhibitor that binds to
many protein kinases with high affinity and little selectivity.11 In
a previous study we reported kinobead profiling of
staurosporine in primary chronic lymphocytic leukemia cells17
and demonstrated that more than a third of the observed
human kinome (41/112) displayed submicromolar IC50 values
(Figure 3). This pan-kinase activity was retained against the T.
brucei kinome, with more than a third of the observed
trypanosome kinome (18/44) displaying IC50 values <1 μM,
including 10 with IC50 values below 100 nM (Figure 3).
The second kinase inhibitor to be profiled, BMS-387032, an
established pan-cyclin-dependent kinase (CDK) inhibitor, was
selected because T. brucei have a relatively expanded CMGC
group including many putative CDK or CDK-like (CDKL)
family members.4,5 Kinobead profiling of BMS-387032 against
primary chronic lymphocytic leukemia cells showed that all of
the seven observed CDKs were inhibited, with CDK2, CDK9,
CRK7, and PCSTAIRE2 displaying submicromolar IC50 values
(Figure 3).17 BMS-387032 retained the ability to inhibit the
majority of the observed trypanosome CDKs, including
targeting the CDK2-related kinases CRK2 and CRK3 with
submicromolar potency (IC50 of 148 and 57 nM, respectively),
although no inhibition of CRK1 was observed (Figure 3). In
addition, the compound selectivity was slightly broader than
just the CDKs, with two additional kinases (CMGC and
CAMK) also inhibited with IC50 values below 500 nM, which
may reflect the divergence of the trypanosome kinome. These
data provide the first molecular evidence that the trypanosome
kinome is sensitive to typical mammalian kinases inhibitors
with nanomolar potencies and suggest that other standard
kinase inhibitor scaffolds may retain substantial activity.
Profiling Trypanosome Kinase Inhibitors. The Drug
Discovery Unit at the University of Dundee has conducted a
number of screening campaigns to help identify preclinical
candidates for the treatment of African sleeping sickness,
including target-based screens against the T. brucei protein
kinases Glycogen Synthase Kinase 3 (GSK3, Tb427.10.13780)
and the Nuclear DBF-2-related (NDR) kinases PK50
(Tb427.10.4940) and PK53 (Tb427.07.5770).8 Details of the
compound screening and optimization will be reported
elsewhere. To further probe the chemical space that
mammalian and trypanosome kinase inhibitors occupy and
demonstrate the utility of chemical proteomics in antiparasitic
drug discovery, we profiled hits selected from these screens
(Supplementary Tables S6 and S7). The compounds selected
all show nanomolar potency against their respective molecular
target in vitro and variable efficacy against cultured trypanosome
and human hepatocyte (MRC5) cells (Table 1).
Table 1. Trypanosome Kinase Inhibitors
GSK3 PK50 PK53
compound ID DDD85893 DDD34425 DDD88213
T. brucei enzyme IC50
(μM)a
<0.002 0.013 ± 0.006 0.73 ± 0.14
T. brucei kinobead IC50
(μM)b
<0.039 not observed 5.7
T. brucei EC50 (μM)
c 1.3 ± 1.2 0.86 ± 0.52 45 ± 4
H. sapiens MRC5 EC50
(μM)c
28 ± 9.7 >50 >50
H. sapiens kinobead IC50
(μM)b
<0.06 not observed not observed
aEnzyme IC50 values were determined using a plate-based radiometric
assay. bKinobead IC50 is described in Methods.
cCell EC50 values were
determined using an Alamar blue assay.34
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The compound DDD85893 was identified as a potent
inhibitor of T. brucei GSK3 (TbGSK3) in vitro, with good
efficacy against cultured T. brucei and good selectivity against
cultured human cells. The kinobead profiling of DDD85893
against T. brucei cell lysates confirmed that TbGSK3 was
inhibited with nanomolar potency, with three other CMGC
kinases inhibited at micromolar level (Figure 4). The
compound also showed a very clean profile against human
MRC5 cell lysates, with only human GSK3α, GSK3β, and
CDK9 inhibited with nanomolar potency. These data show that
the compound DDD85893 has excellent selectivity for GSK3
and limited other CMGC members but does not display any
species specificity.
The second compound to be profiled (DDD34425) was
identified as a potent inhibitor of T. brucei PK50 in vitro, with
good efficacy against cultured T. brucei and good selectivity
against cultured human cells. Unfortunately, the expected target
PK50 was not among the kinases that bound to the kinobeads,
Figure 4. Chemical proteomics profiling of trypanosome kinase inhibitors against the kinome of bloodstream form T. brucei. Horizontal bars
represent IC50 value calculated from the isobaric reporter signals; gray bars indicate where binding was not quantified. Lysates were incubated with
varying concentrations of compounds prior to incubation with kinobeads, and the bound fraction was quantified by tandem mass spectrometry. Data
for TK, TKL, atypical, and lipid kinase are not shown for clarity; the full data can be found in Supplementary Tables S6 and S7.
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suggesting that the ATP binding site contains features that are
not recognized by the set of standard ligands immobilized on
the beads. Indeed, none of the four human NDR kinases
(NDR1, NDR2, LATS1, LATS2) were among the kinases in
MRC5 lysates that bound to the kinobeads. However, the
kinobead profile of DDD34425 against T. brucei cell lysates
revealed that MAPK10 and MAPK5 were inhibited with
nanomolar potency, with three other kinases inhibited at
micromolar level (Figure 4). As T. brucei bloodstream form
MAPK5 null mutants grow normally in vitro18 and little is
known about MAPK10,19 it is unclear what effect, if any, their
inhibition may contribute to the observed trypanocidal effect of
DDD34425. The kinobead profile against MRC5 cell lysates
showed a broader specificity, with the MAPK NKL and TKLs
RIPK2 and ALK2 inhibited with nanomolar potency. Six
additional kinases from four different groups were inhibited at
the micromolar level. These data revealed that the compound
DDD34425 lacks specificity against the observable trypano-
some kinome and significant poly pharmacology against the
observable human kinome, including a number of tyrosine-
specific kinases that are absent from T. brucei.
The compound DDD88213 was identified as a submicro-
molar inhibitor of T. brucei PK53 in vitro but lacked efficacy
against both cultured T. brucei and human cells. The kinobeads
profile of DDD88213 against T. brucei cell lysates revealed that
PK53 was inhibited with an IC50 of 5.7 μM, with CK2α2 also
inhibited with similar potency (Figure 4). The 10-fold drop in
potency between the enzyme IC50 and the kinobeads binding
assay is not significantly different from that seen with other
inhibitors and may reflect differences between purified proteins
and cell extracts. Moreover, the potency determined with
kinobeads is in line with the weak activity of the compound in
the Alamar blue assay. The kinobead profile against MRC5 cell
lysates showed that none of the observable human kinome was
significantly inhibited by DDD88213. These data show that
while this compound does appear to be specifically targeting
the desired trypanosome kinase and appears to have little effect
on the human kinome, it lacks sufficient potency to achieve the
desired trypanocidal effect and would require further
optimization.
The final compound to be profiled was recently identified as
a potent inhibitor of the Leishmania major cyclin dependent
kinase 2-related kinase 3 (LmCRK3) (compound 33, Cleghorn
et al.20) but lacked efficacy against cultured L. major or the
related parasite T. brucei.20 As active recombinant T. brucei
CRK3 (TbCRK3) is not available for in vitro screening, we
attempted to use kinobead profiling to investigate whether the
lack of cellular potency against T. brucei was due to lack of
potency against TbCRK3. The kinobead profile of the
compound revealed that none of the observed T. brucei kinases
were significantly inhibited, including TbCRK3, and neither
were any mammalian kinase (Supplementary Tables S6 and
S7). The complete lack of inhibition suggests that the native
state of parasite CRK3s is distinct from the recombinant form
used for in vitro screening. While these differences may be due
to the absence of the associated cyclin, a recent screen against
LmCRK3-cyclin 6 also resulted in compounds that lacked
efficacy against cultured L. major.21
Summary and Conclusions. We set out to examine the
similarity of the chemical space that parasite and mammalian
protein kinase inhibitors occupy using a recently developed
chemical proteomics approach to profile kinase inhibitors. The
data presented here represent the first molecular evidence that
typical ATP-competitive inhibitors can retain low nanomolar
potency against T. brucei protein kinases. The inhibition profile
of the compounds does not seem to map directly between the
two species, suggesting that it may be possible to exploit these
differences to obtain host/parasite specificity. It is also possible
that the differences observed are an artifact due to the limited
coverage of the kinome achieved by kinobead enrichment.
However, the lack of bias in the enriched kinome suggested that
this is unlikely.
Our data suggest that phenotypic screening of known kinase
inhibitors against T. brucei is likely to identify potent
compounds but also show that it is inappropriate to infer the
molecular target on the basis of the inhibition profile
established in mammalian systems. The chemoproteomics
approach presented to profile potential kinase inhibitors
simultaneously covers as much as half the observed blood-
stream form kinome, representing a 10-fold increase in the
selection of active parasite kinases currently available for drug
discovery. Development of kinobeads tailored to the
trypanosome kinome, for instance, by immobilizing novel
inhibitors identified through phenotypic screening, is an
attractive approach to extend the coverage of the parasite
kinome. Importantly, the approach presented here is species-
independent and can be applied to any clinically relevant
pathogen for which a genome sequence is available.
■ METHODS
Reagents and Drugs. All reagents were purchased from Sigma
unless otherwise noted. Staurosporine was purchased from IRIS
Biotech, and BMS-387032 was custom synthesized by Park Place
Research.
Preparation of Bloodstream Form T. brucei Cell Lysates.
Bloodstream form T. brucei brucei variant 117 (MITat1.4) was purified
from infected rodent blood over DE52 cellulose as described
previously.22 The cells were centrifuged at 800 × g for 10 min at 4
°C and resuspended at 1 × 109 cells/mL in ice-cold buffer 1 containing
protease and phosphatase inhibitors (0.1 mM TLCK, 1 μg/mL
Leupeptin, 1 μg/mL aprotinin, 1 mM PMSF, 1 mM benzamidine,
Phosphatase Inhibitor Cocktail II (Roche)), and hypotonic lysis was
allowed to proceed for 10 min on ice. An equal volume of ice-cold
buffer 2 (100 mM Tris pH 7.5, 10% glycerol, 300 mM NaCl, 50 mM
NaF, 3 mM MgCl2, 0.2 mM Na3VO4, 1.6% Igepal-CA630, 2 mM
DTT, 0.1 mM TLCK) was added, and the lysate was centrifuged at
145,000 × g for 1 h at 4 °C. The BCA assay (Pierce) was used to
determine the total protein content in the supernatant, and the
concentration was adjusted to 5 mg/mL. Aliquots were frozen in liquid
nitrogen and stored at −80 °C prior to use.
Preparation of H. sapiens MRC5 Cell Lysates.MRC5 cells were
grown at 37 °C, 5% CO2 in MEM supplemented with 10% FCS. Cell
lysates were prepared washing the cells briefly in PBS, incubating with
an equal volume of buffers 1 and 2 for 15 min, and then processing the
crude lysate as described above.
Proteomic Analysis. The total proteome was determined in
duplicate by fractionating 25 μg of the bloodstream form T. brucei cell
lysate by SDS-PAGE and pixilation into 24 bands, followed by in-gel
reductive alkylation and tryptic digest. Samples were analyzed by liquid
chromatography − tandem mass spectrometry on a Eksigent 1D+
HPLC system coupled to a LTQ-Orbitrap mass spectrometer
(Thermo scientific). MS spectra were searched using Mascot (Matrix
Science) against a nonredundant, in-house compiled database of
Trypanosoma brucei 927 and 427 strains obtained from TriTrypDB 3.0
23 with additional protein sequences from SwissProt and RefSeq
databases, as well as known contaminant sequences such as keratins
and trypsin. To assess the false discovery rate (FDR) “decoy” proteins
(reverse of the protein sequence) were added to the database. Protein
identifications were accepted as follows: (i) For single spectrum to
sequence assignments, we required the assignment to be the best
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match and a minimum Mascot score of 37 and a 10× difference of the
assignment over the next best assignment. On the basis of these
criteria, the decoy search results indicated <1% false discovery rate
(FDR). (ii) For multiple spectrum to sequence assignments and using
the same parameters, the decoy search results indicate <0.1% FDR. To
make our data accessible to the scientific community, we have
uploaded the results of this study to TriTrypDB (http://www.
tritrypdb.org).23
Kinobead Profiling. Procedures are essentially as described
previously.11,17,24 Kinobeads were prepared by immobilization of
ATP-mimetics on sepharose beads, with the four versions differing in
the identity of the immobilized kinase ligands, as described in
Supplementary Table S8.
For kinobead profiling, compounds were dissolved in DMSO,
added at various concentrations (0, 0.039, 0.156, 0.625, 2.5, and 10
μM) to 1-mL cell lysate samples, and incubated for 45 min at 4 °C.
Subsequently, kinobeads were added to each sample and incubated for
a further 60 min at 4 °C. The kinobeads were collected by
centrifugation and washed with lysis buffer containing 0.2% Igepal-
CA630, and bead-bound proteins were eluted with NuPAGE LDS
buffer (Invitrogen) containing 50 mM DTT for 30 min at 50 °C
followed by alkylation with 20 mg/mL iodoacetamide for 30 min.
Samples were purified on 4−12% NuPAGE gels, stained with colloidal
Coomassie blue, digested with trypsin, and subsequently labeled with
TMT isobaric tagging reagents (ThermoFisher Scientific).15 Tryptic
peptides were separated over 4 h using nanoflow reversed-phase
chromatography online coupled to an Orbitrap mass spectrometer.
Peptide fragmentation was performed using PQD, and peptides were
identified with Mascot and quantified as described.25
Identification of the T. brucei 427 Strain Kinome. The
annotated proteins from T. brucei brucei 427 strain was obtained from
TriTrypDB 3.023 and scanned through a highly sensitive and specific
multilevel HMM library of the protein kinase superfamily,26 followed
by expert curation. Assignment of putative protein kinases to the main
ePK and aPK groups was done by using the E-value cutoffs specific for
each group as described previously.26,27 This procedure identified and
assigned 187 protein kinases (Supplementary Table S1).
Phylogenetic Analysis. The phylogeny of the kinase groups
identified in T. brucei 427 strain was determined using the Phylogeny.fr
platform28 and comprised the following steps: Sequences were aligned
with T-Coffee (v6.85) using pairwise alignment methods,29 and
ambiguous regions (i.e., containing gaps and/or poorly aligned) were
removed with Gblocks (v0.91b)30 with low stringency (Min. seq. for
flank pos.: 55%, Max. contig. nonconserved pos.: 8, Min. block length:
5, Gaps in final blocks: half). The phylogenetic tree was reconstructed
using the maximum likelihood method implemented in the PhyML
program (v3.0 aLRT)31 with reliability for internal branch assessed
using the aLRT test (minimum of SH-like and Chi2-based
parametric).32 Graphical representation and editing of the phyloge-
netic tree was performed with TreeDyn (v198.3).33
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